1.Survey of Attitudes toward the Refill System among Patients on Long-Term Drug Treatment
Koji NARUI ; Toshikazu TAKEDA ; Shinya ABE ; Kazuhiko NOMURA
Japanese Journal of Drug Informatics 2025;26(4):198-207
		                        		
		                        			
		                        			Objective: Of the total number of prescriptions received, the percentage of refill prescriptions in May-June 2022 was 0.053%. In order to speculate on the reasons for the low utilization rate of the refill system and future developments, we surveyed patients who have been receiving continuous drug treatment for more than 6 months to determine their attitudes toward the refill system.Methods: The survey was conducted on the Web and valid responses were obtained from 290 respondents.Results: The respondents were 44.8% male and 55.2% female, with a mean age of 45.6 ± 10.5 years. Respondents' diseases included hypertension (32.1%), dyslipidemia (15.9%), diabetes (15.2%), psychiatric diseases (10.0%), skin diseases (9.3%), and others. Of the respondents, 83.4% had no prescription change within 6 months, and 69.0% had access to treatment medications for the purpose of going to the hospital, indicating that their symptoms were stable and they could use the refill system. In addition, we found that only 17.2% were aware of the refill system. However, 73.4% of respondents indicated their intention to use the refill system in the future. Therefore, our results strongly suggest that the reason for the lack of its use is due to a lack of awareness of it.Conclusion: It is expected that the refill system will be promoted in the future through awareness-raising events and education of the public. It is thought that the use of the refill system may cause delays in the detection of adverse drug reactions and the overlooking of worsening health conditions. The issue is whether pharmacists can appropriately judge whether or not to continue refill prescriptions.
		                        		
		                        		
		                        		
		                        	
2.Neuroendocrine carcinoma associated with chronic ulcerative colitis: a case report and review of the literature
Yumi YOKOTA ; Hiroyuki ANZAI ; Yuzo NAGAI ; Hirofumi SONODA ; Takahide SHINAGAWA ; Yuichiro YOSHIOKA ; Shinya ABE ; Yuichiro YOKOYAMA ; Hiroyuki MATSUZAKI ; Shigenobu EMOTO ; Koji MURONO ; Kazuhito SASAKI ; Hiroaki NOZAWA ; Tetsuo USHIKU ; Soichiro ISHIHARA
Annals of Coloproctology 2024;40(Suppl 1):S32-S37
		                        		
		                        			
		                        			 Adenocarcinoma is a common histological type of ulcerative colitis-associated cancer (UCAC), whereas neuroendocrine carcinoma (NEC) is extremely rare. UCAC is generally diagnosed at an advanced stage, even with regular surveillance colonoscopy. A 41-year-old man with a 17-year history of UC began receiving surveillance colonoscopy at the age of 37 years; 2 years later, dysplasia was detected in the sigmoid colon, and he underwent colonoscopy every 3 to 6 months. Approximately 1.5 years thereafter, a flat adenocarcinoma lesion occurred in the rectum. Flat lesions with high-grade dysplasia were found in the sigmoid colon and surrounding area. The patient underwent laparoscopic total proctocolectomy and ileal pouch-anal anastomosis with ileostomy. Adenocarcinoma was diagnosed in the sigmoid colon and NEC in the rectum. One year postoperation, recurrence or metastasis was not evident. Regular surveillance colonoscopy is important in patients with long-term UC. A histological examination of UCAC might demonstrate NEC. 
		                        		
		                        		
		                        		
		                        	
3.Essential anatomy for lateral lymph node dissection
Yuichiro YOKOYAMA ; Hiroaki NOZAWA ; Kazuhito SASAKI ; Koji MURONO ; Shigenobu EMOTO ; Hiroyuki MATSUZAKI ; Shinya ABE ; Yuzo NAGAI ; Yuichiro YOSHIOKA ; Takahide SHINAGAWA ; Hirofumi SONODA ; Daisuke HOJO ; Soichiro ISHIHARA
Annals of Coloproctology 2023;39(6):457-466
		                        		
		                        			
		                        			 In Western countries, the gold-standard therapeutic strategy for rectal cancer is preoperative chemoradiotherapy (CRT) following total mesorectal excision (TME), without lateral lymph node dissection (LLND). However, preoperative CRT has recently been reported to be insufficient to control lateral lymph node recurrence in cases of enlarged lateral lymph nodes before CRT, and LLND is considered necessary in such cases. We performed a literature review on aspects of pelvic anatomy associated with rectal surgery and LLND, and then combined this information with our experience and knowledge of pelvic anatomy. In this review, drawing upon research using a 3-dimensional anatomical model and actual operative views, we aimed to clarify the essential anatomy for LLND. The LLND procedure was developed in Asian countries and can now be safely performed in terms of functional preservation. Nonetheless, the longer operative time, hemorrhage, and higher complication rates with TME accompanied by LLND than with TME alone indicate that LLND is still a challenging procedure. Laparoscopic or robotic LLND has been shown to be useful and is widely performed; however, without a sufficient understanding of anatomical landmarks, misrecognition of vessels and nerves often occurs. To perform safe and accurate LLND, understanding the landmarks of LLND is essential. 
		                        		
		                        		
		                        		
		                        	
4.Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats
Shun IGARASHI ; Yuji KASUKAWA ; Koji NOZAKA ; Hiroyuki TSUCHIE ; Kazunobu ABE ; Hikaru SAITO ; Ryo SHOJI ; Fumihito KASAMA ; Shuntaro HARATA ; Kento OKAMOTO ; Keita OYA ; Naohisa MIYAKOSHI
Osteoporosis and Sarcopenia 2023;9(4):121-130
		                        		
		                        			 Objectives:
		                        			Chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) is associated with an increased risk of fragility fractures. Etelcalcetide (EC) is a treatment for SHPT that reduces serum parathyroid hormone (PTH) levels. However, the effects of combined treatment with osteoporosis drugs such as teriparatide (TPTD) remain unclear. This study investigates the combined effects of EC and TPTD on bone in CKD model rats. 
		                        		
		                        			Methods:
		                        			The CKD model was established in 8-week-old male Wistar rats by feeding them a 0.75% adenine diet for 4 weeks. At 20 weeks of age, the rats were divided into 4 groups (n = 9–10 in each group): CKD group (vehicle administration), TPTD group (30 μg/kg, 3 times/week), EC group (0.6 mg/kg, daily), and Comb group (TPTD and EC combined). EC was injected for 12 weeks starting at 20 weeks of age, and TPTD was injected for 8 weeks starting at 24 weeks of age. After treatment, the followings were evaluated: bone mineral density, bone strength, biochemical tests, bone and fat histomorphometry, and micro-computed tomography. 
		                        		
		                        			Results:
		                        			In CKD model rats, the combination of EC and TPTD was more effective in increasing cortical bone thickness and bone strength and inhibiting porosity. In addition, the combined treatment decreased bone marrow adiposity and fibrosis, and it increased bone mass and improved bone microstructure in trabecular bone. 
		                        		
		                        			Conclusions
		                        			With the observed benefits such as improved bone mass, bone strength, structural properties, and bone marrow adiposity, combination therapy may be a potential way to improve bone fragility in CKD. 
		                        		
		                        		
		                        		
		                        	
5.Feature of “qi, Blood, Fluid” Factors in Patients with Sjögrenʼs Syndrome : In Comparison with Patients of Rheumatoid Arthritis in Remission
Takeo ABE ; Masao TAMURA ; Koji OH ; Hiroyuki FUJIWARA
Kampo Medicine 2021;72(3):227-234
		                        		
		                        			
		                        			To determine the body constituents patterns comprised of “qi, blood, fluid” factors associated with oral health-related QOL (OHRQOL) of patients with Sjögren's syndrome (SS), 41 SS patients and 32 RA patients in remission were enrolled. The body constituents patterns were measured by using Terasawa's “qi, blood, fluid” score, and the simple version of yin deficiency questionnaire (yin-deficiency score). OHRQOL were evaluated using the oral health impact profile (OHIP-14). In the first study, the body constituents pattern scores were compared between SS group and RA (in remission) group, using the univariate and multivariate analysis. In the second study, the association between OHIP14 and the body constituents pattern scores was analyzed. In the first study, all the scores were significantly higher in SS group, and the multivariable logistic regression identified yin deficiency (p = 0.02) and blood stasis (p = 0.01) as the significantly associated factors with SS group. In the second study, all the scores, except for the blood stasis pattern, showed positive correlation with OHIP-14. The multiple regression analysis identified qi stagnation (p = 0.003) as the significantly associated factors with OHIP-14. This study revealed that yin deficiency and blood stasis are the significant body constituent patterns in SS patients. In the low OHRQOL cases, qi stagnation should be taken into consideration.
		                        		
		                        		
		                        		
		                        	
6.Analysis of bone in adenine-induced chronic kidney disease model rats
Hikaru SAITO ; Naohisa MIYAKOSHI ; Yuji KASUKAWA ; Koji NOZAKA ; Hiroyuki TSUCHIE ; Chiaki SATO ; Kazunobu ABE ; Ryo SHOJI ; Yoichi SHIMADA
Osteoporosis and Sarcopenia 2021;7(4):121-126
		                        		
		                        			 Objectives:
		                        			The purpose of this study is to investigate the stage of chronic kidney disease (CKD) in adenine-induced CKD model rats by serum analyses, and to examine bone mineral density (BMD), bone strength, and microstructure of trabecular and cortical bone in these rats. 
		                        		
		                        			Methods:
		                        			Eight-week-old, male Wistar rats (n = 42) were divided into 2 groups: those fed a 0.75% adenine diet for 4 weeks until 12 weeks of age to generate CKD model rats (CKD group); and sham rats. The CKD and sham groups were sacrificed at 12, 16, and 20 weeks of age (n = 7 in each group and at 12, 16, and 20 weeks), and various parameters were evaluated, including body weight, renal wet weight, muscle wet weight, renal histology, biochemical tests, BMD, biomechanical testing, and micro-computed tomography (CT). The parameters were compared between the 2 groups at the various time points. 
		                        		
		                        			Results:
		                        			In the CKD model rats, at 20 weeks of age, serum creatinine, phosphorus, and intact-PTH levels were elevated, and serum calcium levels were normal, indicating that the CKD was stage IV and associated with secondary hyperparathyroidism. Decreased BMDs of the whole body and the femur were observed as bone changes, and micro-CT analysis showed deterioration of bone microstructure of the cortical bone that resulted in decreased bone strength in the cortical and trabecular bone. 
		                        		
		                        			Conclusions
		                        			These CKD model rats showed stage IV CKD and appear appropriate for evaluating the effects of several treatments for CKD-related osteoporosis and mineral bone disorder. 
		                        		
		                        		
		                        		
		                        	
7.Diffusion Tensor Imaging of the Spinal Canal in Quantitative Assessment of Patients with Lumbar Spinal Canal Stenosis
Masaki NORIMOTO ; Yawara EGUCHI ; Hirohito KANAMOTO ; Yasuhiro OIKAWA ; Koji MATSUMOTO ; Yoshitada MASUDA ; Takeo FURUYA ; Sumihisa ORITA ; Kazuhide INAGE ; Satoshi MAKI ; Yasuhiro SHIGA ; Hideyuki KINOSHITA ; Koki ABE ; Masahiro INOUE ; Tomotaka UMIMURA ; Takashi SATO ; Masashi SATO ; Masahiro SUZUKI ; Keigo ENOMOTO ; Seiji OHTORI
Asian Spine Journal 2021;15(2):207-215
		                        		
		                        			Methods:
		                        			Study participants comprised five healthy volunteers (mean age, 27.2 years) and 27 patients with LSS (mean age, 58.4 years) who were individually assessed using 3.0 Tesla magnetic resonance imaging. Intraspinal ADC and FA values of 10 intervertebral discs from healthy volunteers and 52 intervertebral discs from LSS patients were measured. Also, intraspinal canal area, Schizas classification (A: normal, B: mild stenosis, C: severe stenosis) and correlations with symptoms were investigated. Clinical symptoms were checked for the presence of low back pain (LBP), intermittent claudication (IMC), and bladder and bowel dysfunction (BBD). 
		                        		
		                        			Results:
		                        			Compared to healthy individuals, LSS patients had significantly lower ADC (
		                        		
		                        	
8.Reduced Intravenous Fluorescein Dose for Upper and Lower Gastrointestinal Tract Probe-Based Confocal Laser Endomicroscopy
Kazuya INOKI ; Seiichiro ABE ; Yusaku TANAKA ; Koji YAMAMOTO ; Daisuke HIHARA ; Ryoji ICHIJIMA ; Yukihiro NAKATANI ; HsinYu CHEN ; Hiroyuki TAKAMARU ; Masau SEKIGUCHI ; Masayoshi YAMADA ; Taku SAKAMOTO ; Satoru NONAKA ; Haruhisa SUZUKI ; Shigetaka YOSHINAGA ; Ichiro ODA ; Takahisa MATSUDA ; Yutaka SAITO
Clinical Endoscopy 2021;54(3):363-370
		                        		
		                        			Background/Aims:
		                        			Probe-based confocal laser endomicroscopy (pCLE) requires the administration of intravenous (IV) fluorescein. This study aimed to determine the optimal dose of IV fluorescein for both upper and lower gastrointestinal (GI) tract pCLE. 
		                        		
		                        			Methods:
		                        			Patients 20 to 79 years old with gastric high-grade dysplasia (HGD) or colorectal neoplasms (CRNs) were enrolled in the study. The dose de-escalation method was employed with five levels. The primary endpoint of the study was the determination of the optimal dose of IV fluorescein for pCLE of the GI tract. The reduced dose was determined based on off-line reviews by three endoscopists. An insufficient dose of fluorescein was defined as the dose of fluorescein with which the pCLE images were not deemed to be visible. If all three endoscopists determined that the tissue structure was visible, the doses were de-escalated. 
		                        		
		                        			Results:
		                        			A total of 12 patients with gastric HGD and 12 patients with CRNs were enrolled in the study. Doses were de-escalated to 0.5 mg/kg of fluorescein for both non-neoplastic duodenal and colorectal mucosa. All gastric HGD or CRNs were visible with pCLE with IV fluorescein at 0.5 mg/kg. 
		                        		
		                        			Conclusions
		                        			In the present study, pCLE with IV fluorescein 0.5 mg/kg was adequate to visualize the magnified structure of both the upper and lower GI tract.
		                        		
		                        		
		                        		
		                        	
9.Limited Clinical Significance of Splenectomy and Splenic Hilar Lymph Node Dissection for Type 4 Gastric Cancer
Aina KUNITOMO ; Kazunari MISAWA ; Yuichi ITO ; Seiji ITO ; Eiji HIGAKI ; Seiji NATSUME ; Takashi KINOSHITA ; Tetsuya ABE ; Koji KOMORI ; Yasuhiro SHIMIZU
Journal of Gastric Cancer 2021;21(4):392-402
		                        		
		                        			 Purpose:
		                        			Type 4 gastric cancer (GC) has a very poor prognosis even after curative resection, and the survival benefit of splenectomy for splenic hilar lymph node (LN; #10) dissection in type 4 GC remains equivocal. This study aimed to clarify the clinical significance of splenectomy for #10 dissection in patients with type 4 GC. 
		                        		
		                        			Materials and Methods:
		                        			The data of a total of 56 patients with type 4 GC who underwent total gastrectomy with splenectomy were retrospectively analyzed. Postoperative morbidity, state of LN metastasis, survival outcomes, and therapeutic value index (TVI) of each LN station were evaluated. TVI was calculated by multiplying the incidence of LN metastasis at each nodal station and the 5-year overall survival (OS) of patients who had metastasis to each node. 
		                        		
		                        			Results:
		                        			Overall, the postoperative morbidity rate was 28.6%, and the incidence of #10 metastasis in the patients was 28.6%. The 5-year OS rate for all patients was 29.9%, and most patients developed peritoneal recurrence. Moreover, the 5-year OS rates with and without #10 metastasis were 6.7% and 39.1% (median survival time, 20.4 vs. 46.0 months; P=0.006). The TVI of #10 was as low as 1.92. 
		                        		
		                        			Conclusions
		                        			The clinical significance of splenectomy in the dissection of #10 for type 4 GC is limited and splenectomy for splenic hilar dissection alone should be omitted. 
		                        		
		                        		
		                        		
		                        	
10.A Survey of Health Hazard Cases Caused by Health-Related Products and Pharmacists’ Roles
Saori TESHIGAWARA ; Yoshiteru MOTEGI ; Shinya ABE ; Hikaru MATSUI ; Hiroshi YAMAGUCHI ; Shouko YOSHIMACHI ; Kazuhiko NOMURA ; Akiko TOMIZAWA ; Koji NARUI
Japanese Journal of Drug Informatics 2021;23(2):61-71
		                        		
		                        			
		                        			Objective: There have been reports of health hazards caused by medical devices, cosmetics, quasi-drugs, daily necessities, hygiene products, etc. (health-related products) sold in pharmacies and drugstores. However, the role pharmacists play in dealing with the health hazards caused by health-related products has not been clarified. Therefore, we conducted a survey on the cases of health hazards related to health-related products and the views of pharmacists.Methods: A questionnaire was administered anonymously by email to 601 pharmacists working in community pharmacies or drugstores between December 11 and 20, 2019.Results: The number of valid responses was 585. The breakdown of health hazard cases where pharmacists counseled customers were 60 for medical devices, 31 for cosmetics, 18 for quasi-drugs, 9 for hygiene products, and 20 for daily necessities and others. Of those 138 cases, 19 cases of medical devices were estimated to have an intermediate risk as a health hazard, and the other 119 cases were all classified as low. Of the cases that the pharmacists were not approached for help, but were aware of, 57 were medical devices (21 high, 31 intermediate, 5 low), 44 were cosmetics (12 intermediate, 32 low), 12 were quasi-drugs (7 intermediate, 5 low), 7 were hygiene products (7 low), and 64 were daily necessities and others (26 high, 34 intermediate, 4 low). With regard to health-related products, 95% of the respondents indicated that they had responded to customer questions with advice.Conclusion: Our results show that there are various cases that could develop into health hazards due to health-related products, and most respondents felt a need to alert the public. As such, pharmacists and other staffs in drugstores will continue to provide health support functions to their customers by advising them on not only pharmaceuticals but also these health-related products.
		                        		
		                        		
		                        		
		                        	
            

Result Analysis
Print
Save
E-mail